Switch to: References

Add citations

You must login to add citations.
  1. Redimensión de las políticas públicas frente al acceso a medicamentos: entre la ausencia, la permisividad y el abandono estatal.Iván Vargas-Chaves - 2015 - Estudios Socio-Jurídicos 17 (1):169-193.
    El problema del acceso a los medicamentos no obedece siempre al rol cuestionable de la industria farmacéutica, como sí en gran medida a los Estados, responsables inmediatos por el abandono de millones de pacientes en los países bajo el umbral de pobreza y desarrollo. Para evidenciar esta información se plantean tres escenarios en los que las políticas públicas aún tienen una gran tarea pendiente: la ausencia de regulación y vigilancia, la permisividad con prácticas seudocientíficas y el abandono en regiones apartadas. (...)
    Download  
     
    Export citation  
     
    Bookmark   1 citation  
  • Specifying Rights: the Case of TRIPS.G. Collste - 2011 - Public Health Ethics 4 (1):63-69.
    The TRIPS agreement has been widely discussed. Critics have accused it to favour property rights at the cost of public health in AIDS-stricken development countries. In this article, the conflict between on the one hand Intellectual Property Rights and on the other a right to subsistence is analysed with the help of a method for specification. The rationalization of TRIPS and its amendments raises two questions for ethics, one normative and one meta-ethical. First, which right has priority: the right to (...)
    Download  
     
    Export citation  
     
    Bookmark   5 citations  
  • Ethical Issues Surrounding Intellectual Property Rights.Jorn Sonderholm - 2010 - Philosophy Compass 5 (12):1107-1115.
    Much of today’s international trade is conducted according to trade agreements that involve substantial and uniform protections of intellectual property rights. Intellectual property rights are a socio‐economic tool that create a temporary monopoly for inventor firms and enable such firms to charge prices for their innovations that are many times higher than the marginal cost of production of the innovations. This allows the inventor firms to salvage their research‐costs and secure a profit on their innovations. A large body of contemporary (...)
    Download  
     
    Export citation  
     
    Bookmark   5 citations  
  • The Political and Ethical Challenge of Multi-Drug Resistant Tuberculosis.Ross Upshur, Ian Kerridge, Wendy Lipworth, Christopher Mayes & Chris Degeling - 2015 - Journal of Bioethical Inquiry 12 (1):107-113.
    This article critically examines current responses to multi-drug resistant tuberculosis and argues that bioethics needs to be willing to engage in a more radical critique of the problem than is currently offered. In particular, we need to focus not simply on market-driven models of innovation and anti-microbial solutions to emergent and re-emergent infections such as TB. The global community also needs to address poverty and the structural factors that entrench inequalities—thus moving beyond the orthodox medical/public health frame of reference.
    Download  
     
    Export citation  
     
    Bookmark   5 citations  
  • Patent Funded Access to Medicines.Tom Andreassen - 2014 - Developing World Bioethics 15 (3):152-161.
    Instead of impeding access to essential medicines in developing countries, the essay explores why and how patents can serve as a source of funding for the much needed access to medicine. Instead of a weakening of patents, prolonged protection periods are suggested in circumstances where there is widespread lack of access. The revenues from extended patents are seen as a source of funding for drug donations to the least developed countries.
    Download  
     
    Export citation  
     
    Bookmark